U.S. FDA Accepts Takeda's New Drug Application for Zasocitinib in Plaque Psoriasis Under Priority Review

Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zasocitinib (TAK-279) under Priority Review. Zasocitinib is an investigational, highly selective oral tyrosine kinase 2 (TYK2) inhibitor intended for the treatment of adults with moderate-to-severe plaque psoriasis, having demonstrated rapid, durable, and consistent skin clearance in Phase 3 trials.